ImmunityBio, Inc. IBRX

ImmunityBio, has huge insider ownership, is advancing its ANKTIVA treatment for BCG-unresponsive non-muscle invasive bladder cancer. Recent FDA acceptance of its supplemental Biologics License Application could expand ANKTIVA's indications. Expected revenue growth of 47.8% annually, ImmunityBio additional revenue and sales growth with additional use approvals could lead to exponential growth. Analysts agree on stock price appreciation, and the company currently trades significantly below estimated fair value of at least $15. With expanded use for multiple tumors and treatment of Lymphopenia plus sepsis and a possible AIDS cure CURE the upside share price could be over $300.....

I have owned IBRX for over 3 years and even I am at time losing faith and belief with the constant attack from shorts, share price manipulation, evil attorneys and the media MSM blackout for ImmunityBio news.

But then I remind myself of the science,
the evidence of positive clinical trial results and I know I have INVESTED in a huge winner.

ImmunityBio and all that can be helped with Anktiva we need Trump RFK Jr. and others to pressure the FDA to accelerate wide spread approval and Anktiva for Lymphopenia. ALC is critical and needs to be treated to help cure people and extend their lives.

👉Daredevil👿👈 🖕🖕🖕🖕🖕🖕👎😡

I can really pick a winner. Other people buy stocks and see them rocket higher I pick them and it seems the government is against them and many others try to destroy and hold them back.

ImmunityBio should be all over the MSM news and should have multiple FDA approvals. Blows my mind how corrupt America is.......

Maybe I should hope for a buyout? My fear is a buyout will equal a very slow roll out and more and more people die

👉Daredevil 👿👈. 🖕off

FDA is so corrupted it need a house cleaning

Annual meeting is about electing re electing officers mundane stuff that's generally it